Dr. Rom Samuel Leidner, MD

Dr. Leidner practices at Providence Portland Medical Center in Portland, Oregon, part of Providence Health & Services.

Dr. Leidner's NPI, 1801908702, was assigned on August 31, 2006. Dr. Leidner holds Oregon license MD159938.

Dr. Leidner's primary practice is Providence Portland Medical Center, at 4805 NE Glisan Street, Portland, OR 97213 in Multnomah County. The practice phone is (503) 215-1111.

Dr. Leidner's primary practice is Providence Portland Medical Center in Portland, Oregon, part of Providence Health & Services. Dr. Leidner is also affiliated with Providence St. Vincent Medical Center. The medical group on file is Providence Medical Group, Oregon. Dmand AI also links Dr. Leidner to 1 more hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leidner practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Leidner's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Leidner's licenses on file in 3 states: Oregon, Ohio and Washington.

CMS data shows 344 Medicare services from Dr. Leidner across 4 procedure codes in 2024, for 46 Medicare patients. Medicare paid $21,221 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 46 Medicare patients who saw Dr. Leidner in 2024. The largest group is 65 to 74, with 30 patients. 61% of them have high blood pressure, and 43% have high cholesterol. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leidner's median patient age at 69, with 22% women.

In 2024, Dr. Leidner wrote 582 Medicare Part D claims for 62 patients. 93% of them were for generic drugs. CMS names the drug for 398 of them, across 17 drugs with 11 or more claims each, at $389,811 in total drug cost. In 2023, CMS named 355 claims across 15 drugs.

Dr. Leidner accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leidner as offering telehealth.

Dmand AI links 47 papers to Dr. Leidner, published from 2011 to 2025. 2019 was the busiest year, with 7. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Immunotherapy. Dr. Leidner has published most often in Oral Oncol. Dr. Leidner's most frequent co-authors are Marka Rae Crittenden, MD, PhD, Richard Bryan Bell, DDS, MD and Walter John Urba, MD, PhD.

Dmand AI links Dr. Leidner to 10 clinical trials, 5 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms and Carcinoma, Squamous Cell. Providence Health & Services sponsors the most, 7.

CMS Open Payments shows 128 general payments to Dr. Leidner from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 51% of the total. Sanofi and Genzyme US Companies paid the most, $21,180. It also lists 1 research payment totaling $1,087 in 2020.